CN112089738A - Preparation method and application of caulis sinomenii extract - Google Patents
Preparation method and application of caulis sinomenii extract Download PDFInfo
- Publication number
- CN112089738A CN112089738A CN202011222133.5A CN202011222133A CN112089738A CN 112089738 A CN112089738 A CN 112089738A CN 202011222133 A CN202011222133 A CN 202011222133A CN 112089738 A CN112089738 A CN 112089738A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese
- preparation
- extracting
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 43
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 37
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940116269 uric acid Drugs 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000006286 aqueous extract Substances 0.000 claims abstract description 22
- 238000010438 heat treatment Methods 0.000 claims abstract description 19
- 238000010828 elution Methods 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 238000004440 column chromatography Methods 0.000 claims abstract description 12
- 241001529849 Dracocephalum Species 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract description 11
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 239000000741 silica gel Substances 0.000 claims abstract description 7
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 241000345998 Calamus manan Species 0.000 claims abstract description 5
- 235000012950 rattan cane Nutrition 0.000 claims abstract description 5
- 235000017186 Celastrus paniculatus Nutrition 0.000 claims abstract description 3
- 241000296615 Celastrus strigillosus Species 0.000 claims description 20
- 239000012153 distilled water Substances 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 208000010380 tumor lysis syndrome Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 241001655728 Celastrus Species 0.000 claims description 2
- 241000209445 Nelumbonaceae Species 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000008901 benefit Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 240000006739 Celastrus paniculatus Species 0.000 abstract 1
- 244000195896 dadap Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 235000008216 herbs Nutrition 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241000296609 Celastrus angulatus Species 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 241001643409 Sinomenium acutum Species 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000018436 Coriandrum sativum Species 0.000 description 3
- 235000002787 Coriandrum sativum Nutrition 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001643412 Sinomenium Species 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940117336 parsley extract Drugs 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229930014594 aporphine alkaloid Natural products 0.000 description 2
- 150000008441 aporphines Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- -1 coumarin, lactone Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003808 methanol extraction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000142531 Clonostachys Species 0.000 description 1
- 241001076416 Dendrobium tosaense Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001280362 Illigera Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 239000005868 Metconazole Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241001604597 Pyrestini Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940084627 colchicine 0.5 mg Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XWPZUHJBOLQNMN-UHFFFAOYSA-N metconazole Chemical compound C1=NC=NN1CC1(O)C(C)(C)CCC1CC1=CC=C(Cl)C=C1 XWPZUHJBOLQNMN-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method and application of a Chinese medicine extract, namely Chinese medicine extract of Chinese medicineIlligera aromaticfa S.Z.Huang et S.L.Mo) Is the dried rattan of the Chinese ivy of the celastrus of the erythrina, the extract of the Chinese ivy is the ethanol elution part of the aqueous extract of the Chinese ivy, and the extraction method comprises the following steps: pulverizing caulis sinomenii into fine powder, adding a proper amount of water, heating and extracting for 2-4 times, collecting an extracting solution, and concentrating to 1.0-1.2 g/m; and performing column chromatography separation on the concentrated solution by using a silica gel chromatographic column, performing gradient elution by using ethanol with different concentrations as a mobile phase, collecting each eluate, and concentrating to obtain an extract. The extract of the Chinese dutchmanspipe vine can be applied to the preparation of medicines for treating/preventing hyperuricemia and related diseases or regulating uric acid functions. The invention discovers for the first time that the Chinese moldavica dragonhead extractive has obvious activity of regulating uric acid, has the patent medicine potential of preparing the medicinal preparation for preventing or treating hyperuricemia and related diseases thereof, and has simple preparation method, low cost and good patent medicine economic benefit.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method and application of a Chinese moldavica dragonhead extract.
Background
Uric acid is the terminal metabolite of human purine compounds, and disorders of purine metabolism lead to Hyperuricemia (HUA). Hyperuricemia refers to the condition that under the normal purine diet state, the level of uric acid in non-bidaily fasting blood is higher than 420 mu mol/L in male, and higher than 360 mu mol/L in female, namely hyperuricemia is called. Gout (gout) is a group of metabolic diseases caused by excessive uric acid production caused by purine metabolic disorder and/or reduction of uric acid excretion to increase uric acid level and form uric acid crystals deposited on joints, soft tissues, kidneys and the like. Hyperuricemia is generally considered a hallmark of gout, and it is statistically estimated that about 5% to 12% of patients with hyperuricemia may eventually develop gout. In addition, recent studies have found that hyperuricemia is not only the most important biochemical basis of gout, but also is closely related to the occurrence of hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, the severity of infectious diseases, tumor lysis syndrome, climacteric syndrome, organ transplantation complications and certain problematic conditions (obstructive sleep apnea, primary sicca syndrome, etc.), so that control of hyperuricemia is of great significance for the treatment of severe metabolic diseases such as gout and the like and diseases related thereto.
Currently, drugs for clinical use against hyperuricemia are mainly concerned with both reducing uric acid production and increasing uric acid excretion. The medicine for reducing the uric acid generation comprises a Xanthine Oxidase (XOD) inhibitor, which mainly comprises allopurinol, but the allopurinol can cause adverse reactions such as allergy, liver and kidney damage, bone marrow suppression and the like, and limits the clinical application of the medicine to a certain extent. fexbuxostat is a xanthine oxidase/dehydrogenase selective inhibitor, has better safety than allopurinol for patients with moderate renal injury, and also has adverse reactions reported such as abnormal liver function, gastrointestinal reaction, arthralgia, eruption and the like. The uricosuric drugs comprise probenecid, metconazole, benzbromarone and the like, and act on a urate transporter of a renal proximal convoluted tubule so as to inhibit the reabsorption of uric acid. Recent studies have found that benzbromarone is at risk of causing fulminant hepatitis. Therefore, the research on the anti-hyperuricemia drugs with high efficiency and low toxicity is urgent. Researches in recent years find that the traditional Chinese medicine also has a good effect on treating hyperuricemia and shows little or no toxic and side effects. Such as: patent application CN109700837A discloses that one or a mixture of two of n-butanol extract or alcohol soluble part extract of plateau nettle has the effects of resisting hyperuricemia, inhibiting liver XOD activity and regulating kidney uric acid transporter gene expression, and can be used for preparing medicines for resisting hyperuricemia. Patent CN104383292B discloses that the extract enriched in total polyphenols of Dendrobium officinale Kimura et Migo can be used as active ingredient for preparing medicine for treating hyperuricemia, can reduce the concentration of uric acid in blood, has remarkable effect on treating hyperuricemia, and has no toxic and side effects. Patent CN103191235B discloses that the mixed alcohol extract of three herbs of kudzuvine root, tangerine peel and pine needle can reduce UA level in serum of rat with hyperuricemia, reduce XOD activity in serum and liver, and reduce ADA activity in serum and liver. And so on. Therefore, the extract of a large number of Chinese medicinal materials or the Chinese medicinal compound preparation has the patent medicine potential for preparing the medicament for treating the hyperuricemia, and the Chinese medicinal material has the advantages of small side effect, strong comprehensive treatment capacity and the like, so that the development of the new application of the Chinese medicinal material extract actively explores a potential medicament target of a new medicament for treating the hyperuricemia, and the search for a novel medicament for treating the hyperuricemia is an important problem which needs to be solved clinically at present.
Caulis Seu folium Parthenocissi Tricuspidatae (caulis Parthenocissi Tricuspidatae)Illigera aromaticfa S.Z.Huang et S.L.Mo) Is a dry rattan of the celastrus orbiculatus of celastrus of the family erythrinae, has fragrant smell, pungent and cool taste, is mainly distributed in Guangxi and is a unique vine resource in China. Caulis Sinomenii has effects of dispelling pathogenic wind, removing dampness, activating qi-flowing, relieving pain, relieving rigidity of muscles and activating collaterals, and can be used for treating rheumatalgia, traumatic injury, hypertrophic spondylitis, etc. The caulis Seu folium Schisandrae Henryi containsSugar, polysaccharide, glycoside, saponin, organic acid, flavonoid, anthraquinone, coumarin, lactone, phytosterol, triterpene, volatile oil, etc. At present, the research on the Chinese ivy is less, the research is mainly focused on the aspect of chemical component analysis of the Chinese ivy, and in addition, some Chinese ivy extracts anti-tumor active components; for example, patent CN107384983B discloses a method for producing novel antitumor cytotoxic active compound dimer acids EF by solid fermentation treatment of celastrus angulatus (Clonostachys rogesoniana 828H2) with celastrus angulatus (illinoera aromatica); patent CN107286172B discloses an aporphine alkaloid Illigerine B prepared by taking rattan stems as a raw material and carrying out five steps of methanol extraction, ethyl acetate extraction, primary column chromatography, secondary column chromatography and washing impurity removal, wherein the compound has definite tumor cell inhibition activity and has potential value for developing antitumor drugs; patent CN107043383B discloses an aporphine alkaloid Illigerine A prepared by taking rattan stems as a raw material and carrying out five steps of methanol extraction, ethyl acetate extraction, primary column chromatography, secondary column chromatography, tertiary column chromatography and washing and impurity removal. However, there is no introduction about how to expand the use of the Chinese medicinal herbs to maximize their efficacy and exert their corresponding effects, which is still the main direction of medical research.
Disclosure of Invention
The invention aims to provide a preparation method and application of a Chinese parsley extract, the Chinese parsley extract is found for the first time to have obvious activity of regulating uric acid, and has the patent medicine potential of preparing a medicinal preparation for preventing or treating hyperuricemia and related diseases, and the medicinal preparation has the advantages of simple preparation method, low cost and good patent medicine economic benefit.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of a Chinese parsley extract comprises the following steps:
(1) pulverizing caulis sinomenii into fine powder, adding a proper amount of water, heating and extracting for 2-4 times, collecting an extracting solution, and concentrating to 1.0-1.2 g/mL;
(2) performing column chromatography separation on the concentrated solution by using a silica gel chromatographic column, performing gradient elution by using ethanol with different concentrations as mobile phases, collecting each eluate, and concentrating to obtain an extract to obtain the extract of the Chinese dutchmanspipe vine.
The specific extraction method in the step (1) comprises the following steps:
(1) pulverizing caulis sinomenii into fine powder, adding distilled water with the mass of 4-8 times of that of the caulis sinomenii, soaking for 40-80 min, heating to 80-minus 100 ℃, extracting for 40-80 min, filtering, and collecting filtrate;
(2) adding distilled water with the mass of 4-8 times of that of the filter residue, heating to 80-100 ℃, extracting for 40-80 min, filtering, and collecting filtrate;
(3) and repeatedly extracting the filter residue for 1-3 times, combining the filtrates obtained by multiple extraction, and concentrating to 1.0-1.2 g/mL to obtain the aqueous extract of the Chinese ivy.
The ethanol with different concentrations is ethanol with volume concentration of 0-95%. Selecting a plurality of gradient eluents with the concentration of 0-95% by volume.
Preferably, the different concentrations of ethanol are 0%, 30%, 60%, 75%, 95% ethanol by volume.
The application of the water extract or the extract of the Chinese medicinal material moldavica dragonhead to the preparation of medicaments for treating/preventing hyperuricemia and related diseases or medicaments with the function of regulating uric acid. Preferably, the Chinese ivy extract refers to 30-75% (volume concentration) ethanol elution part of the Chinese ivy aqueous extract.
The hyperuricemia and related diseases are one or more of hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, infectious diseases, tumor lysis syndrome, climacteric syndrome, organ transplantation complications, obstructive sleep apnea and primary sicca syndrome caused by uric acid metabolic disorder.
The extract of the Chinese ivy is selectively added with conventional auxiliary materials and prepared into a clinically acceptable pharmaceutical preparation for treating/preventing hyperuricemia and related diseases or having the function of regulating uric acid according to a conventional process.
The preparation comprises tablets, capsules, dripping pills, granules, tinctures, vinum and the like.
The conventional adjuvants include more than one of starch, lactose, microcrystalline cellulose, dextrin, calcium phosphate, polyethylene glycol-4000, polyethylene glycol-6000, sodium carboxymethylcellulose, hydroxypropyl cellulose or crospovidone, etc.
The invention has the beneficial effects that:
1. the invention discovers for the first time that the Chinese moldavica dragonhead extractive has obvious activity of regulating uric acid, has the patent medicine potential of preparing the medicinal preparation for preventing or treating hyperuricemia and related diseases thereof, provides a new material basis for developing the innovative medicaments for resisting the hyperuricemia, and has potential and huge social benefit and economic benefit.
2. The invention has rich sources of the Chinese ivy, is convenient and easy to obtain, and can be used for preparing a large amount of Chinese ivy extracts. Although the Chinese medicine component has a certain activity of resisting hyperuricemia when the dosage of the Chinese medicine component is high, the dosage is large and the activity is low, therefore, in the preparation method of the Chinese medicine component, the Chinese medicine component is subjected to water extraction for a plurality of times and combined extract to obtain the Chinese medicine component, then the Chinese medicine component is eluted by ethanol with different concentrations to obtain different elution parts, and finally the parts with obvious curative effect on hyperuricemia and related diseases are collected, so that the activity of regulating uric acid of the finally obtained Chinese medicine component and the pharmaceutical preparation thereof is greatly improved; and the whole extraction and preparation method is simple and easy to implement, low in cost, small in pollution, beneficial to large-scale production under the conditions of energy conservation and emission reduction, and good in industrialization prospect.
3. According to the invention, the influence of the Chinese moldavica vine extract on the level of uric acid in blood serum of a mouse with hyperuricemia caused by hypoxanthine and the influence of the Chinese moldavica vine extract on toe swelling of a rat induced by sodium urate are researched, so that the Chinese moldavica vine extract disclosed by the invention has obvious activity of regulating uric acid on the hyperuricemia, and the Chinese moldavica vine aqueous extract also has a certain activity of resisting the hyperuricemia at a high dosage.
4. The Chinese medicine composition has the effects of dispelling wind, promoting blood circulation and the like, can be used for treating diseases such as rheumatic bone pain, traumatic injury, hypertrophic spondylitis and the like, and can play a role in preventing or treating hyperuricemia or gout and treating other complications.
5. The extract of the Chinese ivy is mixed with auxiliary materials to prepare tablets, capsules, dripping pills, granules, tinctures, vinous agents and the like, the preparations are convenient to take, can be taken alone or matched with other medicaments, and can be taken orally to quickly convey the medicament property to the disease part through blood for effective treatment.
Detailed Description
In order to describe the present invention in more detail, the present invention will be further described with reference to the following examples.
Example 1 preparation of an aqueous extract of Celastrus orbiculatus
Pulverizing caulis et folium piperis into fine powder, collecting 1kg of caulis et folium piperis fine powder, soaking in 4L distilled water for 60min, heating to 80 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 4L distilled water into the residue, heating to 80 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 4L distilled water into the residue, heating to 80 deg.C, extracting for 60min, filtering, and collecting filtrate; and combining the extracting solutions for 3 times, and concentrating to 1.0-1.2 g/mL to obtain the compound.
Example 2 preparation of an aqueous extract of Celastrus orbiculatus
Pulverizing caulis Sinomenii into fine powder, collecting 1kg of caulis Sinomenii fine powder, soaking in 6L distilled water for 60min, heating to 90 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 6L distilled water into the residue, heating to 90 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 6L distilled water into the residue, heating to 90 deg.C, extracting for 60min, filtering, and collecting filtrate; and combining the extracting solutions for 3 times, and concentrating to 1.0-1.2 g/mL to obtain the compound.
Example 3 preparation of an aqueous extract of Celastrus orbiculatus
Pulverizing caulis et folium piperis into fine powder, collecting 1kg of caulis et folium piperis fine powder, soaking in 8L distilled water for 60min, heating to 98 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 8L distilled water into the residue, heating to 98 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 8L distilled water into the residue, heating to 98 deg.C, extracting for 60min, filtering, and collecting filtrate; and combining the extracting solutions for 3 times, and concentrating to 1.0-1.2 g/mL to obtain the compound.
Example 4 preparation of an aqueous extract of Celastrus orbiculatus
Pulverizing caulis et folium piperis into fine powder, collecting 1kg of caulis et folium piperis fine powder, soaking in 8L of distilled water for 80min, heating to 80 deg.C, extracting for 80min, filtering, and collecting filtrate; adding 6L distilled water into the residue, heating to 90 deg.C, extracting for 60min, filtering, and collecting filtrate; adding 4L distilled water into the residue, heating to 98 deg.C, extracting for 40min, filtering, and collecting filtrate; and combining the extracting solutions for 3 times, and concentrating to 1.0-1.2 g/mL to obtain the compound.
Example 5 preparation of ethanol elution fraction of an aqueous extract of Celastrus orbiculatus
Taking the concentrated solution of the aqueous extract of the sinomenium acutangtum prepared by the preparation method of the embodiment 3, performing column chromatography separation by using a silica gel chromatographic column, sequentially performing gradient elution by using ethanol with volume concentration of 0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% and 95% as a mobile phase, and respectively collecting each eluate and concentrating the eluate to obtain an extract, namely the sinomenium acutanguticum extract.
Example 6 preparation of ethanol elution fraction of an aqueous extract of Celastrus orbiculatus
Taking the concentrated solution of the caulis sinomenii aqueous extract prepared by the preparation method of the embodiment 3, performing column chromatography separation by adopting a silica gel chromatographic column, performing gradient elution by taking ethanol with volume concentration of 0%, 15%, 30%, 45%, 60%, 75% and 90% as a mobile phase in sequence, collecting each eluate respectively, and concentrating to obtain an extract, namely the caulis sinomenii extract.
Example 7 preparation of ethanol elution fraction of an aqueous extract of Celastrus orbiculatus
Taking the concentrated solution of the caulis sinomenii aqueous extract prepared by the preparation method of the embodiment 3, carrying out column chromatography separation by adopting a silica gel chromatographic column, carrying out gradient elution by taking ethanol with volume concentration of 0%, 30%, 60%, 75% and 95% as a mobile phase in sequence, collecting each eluate respectively, and concentrating to obtain an extract, thus obtaining the caulis sinomenii extract.
Example 8 preparation of ethanol elution fraction of an aqueous extract of Celastrus orbiculatus
Taking the concentrated solution of the caulis sinomenii aqueous extract prepared by the preparation method of the embodiment 3, carrying out column chromatography separation by adopting a silica gel chromatographic column, carrying out gradient elution by taking ethanol with volume concentration of 15%, 35%, 55%, 75% and 95% as a mobile phase in sequence, collecting each eluate respectively, and concentrating to obtain an extract, thus obtaining the caulis sinomenii extract.
Example 9 preparation of a tablet of an extract of Celastrus orbiculatus
[ prescription ] 60% ethanol elution fraction of the aqueous extract of moldavica dragonhead prepared by the method of example 7 (the amount corresponding to 4kg of moldavica dragonhead herb), 300g of dry starch;
[ PREPARATION METHOD ] mixing the 60% ethanol eluted part of the extract of Celastrus angulatus with dry starch, adding appropriate amount of sodium carboxymethylcellulose and pulvis Talci, granulating, drying, and pressing into 1000 tablets to obtain Celastrus angulatus extract tablet, each tablet containing 4g of Celastrus angulatus.
The above-mentioned dry starch, sodium carboxymethylcellulose and talc powder are all commercially available.
Example 10 preparation of a Celastrus orbiculatus extract Capsule
[ prescription ] 60% ethanol elution fraction of the aqueous extract of moldavica dragonhead prepared by the method of example 7 (the amount corresponding to 4kg of moldavica dragonhead herb), 300g of dry starch;
[ PREPARATION METHOD ] mixing the 60% ethanol elution part of the extract of the orienavine with dry starch, adding a proper amount of sodium carboxymethylcellulose and talcum powder, granulating, drying, and encapsulating into 1000 capsules, wherein each capsule contains 4g of orienavine.
The above-mentioned dry starch, sodium carboxymethylcellulose and talc powder are all commercially available.
Example 11 preparation of a granule of an extract of Celastrus orbiculatus
[ prescription ] the 60% ethanol elution fraction of the aqueous extract of moldavica dragonhead prepared by the method of example 7 (corresponding to 8kg of moldavica dragonhead herb) and 300g of dry starch;
[ PREPARATION METHOD ] mixing the 60% ethanol eluted part of the extract of Celastrus angulatus water extract with dry starch, adding appropriate amount of sodium carboxymethylcellulose and pulvis Talci, granulating, drying, and packaging into 1000 bags to obtain Celastrus angulatus extract granule, each bag containing 8g of Celastrus angulatus.
The above-mentioned dry starch, sodium carboxymethylcellulose and talc powder are all commercially available.
Test of drug Property
To verify the activity of the extract of sinomenium perfoliatum of the present invention in modulating uric acid, the applicant carried out the following tests:
1. effect of Celastrus orbiculatus extract on hypoxanthine induced hyperuricemia mouse serum uric acid level
And (3) testing the sample: the Chinese medicinal herbs of the Chinese medicinal herbs include the Chinese medicinal herbs of the embodiment 3, and the Chinese medicinal herbs of the embodiment 7 are 50% ethanol-eluted parts of the Chinese medicinal herbs.
The treatment method comprises the following steps: 90 mice, randomly divided into 9 groups of 10 mice each, namely a normal group, a model group, a positive control group (allopurinol 20 mg.kg)-1) The high, medium and low dosage groups of the extract of the Chinese ivy (respectively equal to 10g.kg of the Chinese ivy medicinal material)-1、5g.kg-1And 2.5g.kg-1) The high, medium and low dosage groups of the Chinese medicine ivy aqueous extract (respectively equal to 10g-1、5g.kg-1And 2.5g.kg-1) Gavage was performed 1 time per day, and equal volume of distilled water was gavage for 12 consecutive days in the normal group and the model group. After the last administration for 1h, except the normal group, the other groups were administered with hypoxanthine 0.4g.kg by gavage-1And after 1h, blood is taken from eyeballs of the mice in each group, centrifugation is carried out for 10min at 1000 Xg, and serum is taken, and the content of uric acid in the serum is determined by adopting a phosphotungstic acid colorimetric method.
As a result: as shown in table 1, compared with the model group, the mouse serum uric acid levels of the mice in the high, medium and low dose groups of the sinomenium acutum extract and the high, medium and low dose groups of the sinomenium acutum extract are all reduced, but the mouse serum uric acid levels of the mice in the high, medium dose groups (the doses are respectively 10g and 5g of the medicinal materials) of the sinomenium acutum extract and the high dose group (the dose is 20g of the medicinal materials) of the sinomenium acutum extract are obviously reduced, and the comparison has statistical significance (P is less than 0.05).
2. Effect of Celastrus orbiculatus extract on sodium urate-induced toe swelling in rats
And (3) testing the sample: the Chinese medicinal herbs of the Chinese medicinal herbs include the Chinese medicinal herbs of the embodiment 3, and the Chinese medicinal herbs of the embodiment 7 are 50% ethanol-eluted parts of the Chinese medicinal herbs.
The treatment method comprises the following steps: 70 rats were randomly divided into 7 groups of 10 rats, i.e., normal group, model group, and positive control group (colchicine 0.5 mg.kg)-1) High and low dose groups of the extract of the Chinese ivy (respectively equivalent to 10g.kg of the Chinese ivy medicinal material)-1And 2.5g.kg-1) The high and low dose groups of the Chinese medicine caulis sinomenii aqueous extract (respectively equal to 20g-1And 10g.kg-1) Gavage was performed 1 time per day, and equal volume of distilled water was gavage for 12 consecutive days in the normal group and the model group. After 1 hour of the last administration, 0.15mL of physiological saline was subcutaneously injected to the right hind sole of the rat in the normal group, and 0.15mL of sodium urate crystals (100 g.L) was subcutaneously injected to the right hind sole of the rat in each of the other groups-1) For inflammation, the circumference of the right hind paw of the rat was measured before and after injection. The swelling condition and the circumference of the right hind foot sole of the rat 2, 3, 5 and 6h after the injection are observed and measured, and the swelling rate is calculated.
Footpad swelling rate =100 (-t time circumference-t)0Time circumference)/t0The time circumference.
As a result: as shown in Table 2, the toe swelling rate of the model rats was significantly increased compared to the control group; compared with the model group, the swelling rate of rats in the high-dose group (dose is 10g medicinal materials) of the sinomenium acutum extract after model building is obviously reduced, and the swelling rate of rats in the low-dose group (dose is 2.5g medicinal materials) of the sinomenium acutum extract after model building is obviously reduced; the swelling rate of rats in the high-dose group (20 g medicinal material) of the Chinese ivy herb water extract after molding is remarkably reduced, the low-dose group (10 g medicinal material) of the Chinese ivy herb water extract has no remarkable influence, and the difference has statistical significance (P is less than 0.05).
Claims (10)
1. A preparation method of a Chinese medicine caulis Celastri sinensis extract, wherein the Chinese medicine caulis Celastri sinensis is dried rattan of Chinese medicine caulis Celastri sinensis of Celastrus of Nelumbonaceae, is characterized by comprising the following steps:
(1) pulverizing caulis sinomenii into fine powder, adding a proper amount of water, heating and extracting for 2-4 times, collecting an extracting solution, and concentrating to 1.0-1.2 g/mL;
(2) performing column chromatography separation on the concentrated solution by using a silica gel chromatographic column, performing gradient elution by using ethanol with different concentrations as mobile phases, collecting each eluate, and concentrating to obtain an extract to obtain the extract of the Chinese dutchmanspipe vine.
2. The preparation method of the Celastrus orbiculatus extract according to claim 1, wherein the specific extraction method in the step (1) is as follows:
(1) pulverizing caulis sinomenii into fine powder, adding distilled water with the mass of 4-8 times of that of the fine powder, soaking for 40-80 min, heating to 80-100 ℃, extracting for 40-80 min, filtering, and collecting filtrate;
(2) adding distilled water with the mass of 4-8 times of that of the filter residue, heating to 80-100 ℃, extracting for 40-80 min, filtering, and collecting filtrate;
(3) and repeatedly extracting the filter residue for 1-3 times, combining the filtrates obtained by multiple extraction, and concentrating to 1.0-1.2 g/mL to obtain the aqueous extract of the Chinese ivy.
3. The method for preparing the Celastrus orbiculatus extract according to claim 1, wherein the volume concentration of ethanol in step (2) is in the range of 0-95%.
4. The method for preparing the Celastrus orbiculatus extract according to claim 3, wherein the volume concentration of ethanol is 0%, 30%, 60%, 75%, 95%.
5. The extract of Celastrus orbiculatus according to any one of claims 1-4.
6. Use of the extract of Celastrus orbiculatus according to claim 5 in the preparation of a medicament for treating/preventing hyperuricemia and related diseases or a medicament having a function of regulating uric acid.
7. The use as claimed in claim 6, wherein the extract of Celastrus orbiculatus is obtained by eluting with 30-75 vol.% ethanol.
8. The use according to claim 6, wherein the hyperuricemia and related disorders are one or more of hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, infectious diseases, tumor lysis syndrome, climacteric syndrome, organ transplantation complications, obstructive sleep apnea and primary sicca syndrome caused by dysregulation of uric acid metabolism.
9. The use according to claim 6 or 7, wherein the extract of the moldavica dragonhead is optionally added with conventional auxiliary materials, and prepared into a clinically acceptable pharmaceutical preparation for treating/preventing hyperuricemia and related diseases or having a function of regulating uric acid according to a conventional process.
10. Use according to claim 9, characterized in that the preparation comprises a tablet, capsule, drop pill, granule, tincture or wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011222133.5A CN112089738A (en) | 2020-11-05 | 2020-11-05 | Preparation method and application of caulis sinomenii extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011222133.5A CN112089738A (en) | 2020-11-05 | 2020-11-05 | Preparation method and application of caulis sinomenii extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112089738A true CN112089738A (en) | 2020-12-18 |
Family
ID=73785416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011222133.5A Withdrawn CN112089738A (en) | 2020-11-05 | 2020-11-05 | Preparation method and application of caulis sinomenii extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112089738A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999730A (en) * | 2021-11-09 | 2022-02-01 | 扬州市东源日化旅游用品厂 | Mite-killing laundry detergent and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771442A (en) * | 2015-02-15 | 2015-07-15 | 广西卫生职业技术学院 | Tinospora sinensis Merr extract, and extraction method and application thereof |
-
2020
- 2020-11-05 CN CN202011222133.5A patent/CN112089738A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771442A (en) * | 2015-02-15 | 2015-07-15 | 广西卫生职业技术学院 | Tinospora sinensis Merr extract, and extraction method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 谢丽莎等: "香青藤化学成分研究", 《当代医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999730A (en) * | 2021-11-09 | 2022-02-01 | 扬州市东源日化旅游用品厂 | Mite-killing laundry detergent and preparation method thereof |
| CN113999730B (en) * | 2021-11-09 | 2024-01-12 | 江西锦润药业有限公司 | Mite-removing laundry detergent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535048A (en) | Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout | |
| CN101116722A (en) | Pharmaceutical formulations with the raw material containing panax, ophiopogon root and schisandra fruit, processes for their preparation, the raw material and the quality control method for the prepa | |
| CN101554409A (en) | Long pepper alkaloid and preparation method, preparation and application thereof | |
| WO2013155995A1 (en) | Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN112089738A (en) | Preparation method and application of caulis sinomenii extract | |
| CN1327859C (en) | Schisandra fruit extractive, its preparation process and purposes | |
| CN1951422A (en) | Pharmaceutical composition for treating disease of liver and gallbladder system and preparation and use thereof | |
| CN101890063B (en) | Chinese medicament for reducing blood sugar and preparation method thereof | |
| CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
| CN1977900A (en) | Chinese medicine for treating skin disease such as psoriasis | |
| CN115025143B (en) | Preparation method and application of chaetoceros extract | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application | |
| CN101380356B (en) | Tibetan medicine Duyiwei total flavone extract and extraction method and use thereof | |
| CN110201014A (en) | A kind of preparation method and applications of Panax stipuleanatus Tsai et Feng total saposins | |
| CN112386642A (en) | Large fan blade extract and preparation method and application thereof | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| WO2013155997A1 (en) | Blood lipid-regulating red yeast ligusticum chuanxiong pharmaceutical composition and preparation method therefor | |
| CN109498737B (en) | Pharmaceutical composition for treating metabolic diseases and preparation method and application thereof | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN116509916B (en) | Erigeron breviscapus active site liposome, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201218 |
|
| WW01 | Invention patent application withdrawn after publication |